# M.D. Anderson Cancer Center: Phase 1 study completed, 15 enrolled (Tumor, Adenocarcinoma)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma |
| NCT ID | NCT05273554 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Tumor; Adenocarcinoma |
| Intervention types | drug |
| Target enrollment | 15 |
| Site countries | United States |
| Posted | 2022-03-10 |
| Planned start | 2022-08-31 |
| Event | Completed |
| Event date | 2026-09-22 |
| Last update posted | 2026-09-29 |

## Why this score
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05273554). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.